PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on
the Impact of Decipher® Testing on Treatment Recommendations in African-American and
Non-African American Men with Prostate Cancer: (VANDAAM)" that had high risk Decipher test
results (Decipher score >0.45). Patients with a high genomic classifier (GC) score at
diagnosis will be approached for formal consenting for PSMA-PET imaging at 2 years post
treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute